Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial

Dan Dang, Dongxuan Wang, Chuan Zhang, Wenli Zhou, Qi Zhou, Hui Wu, Dan Dang, Dongxuan Wang, Chuan Zhang, Wenli Zhou, Qi Zhou, Hui Wu

Abstract

Trial design: Oral ibuprofen has demonstrated good effects on symptomatic patent ductus arteriosus (PDA) but with many contraindications and potential side-effects. In the past two years, oral paracetamol administration to several preterm infants with PDA has been reported. Here, a randomized, non-blinded, parallel-controlled and non-inferiority trial was designed to evaluate the efficacy and safety profiles of oral paracetamol to those of standard ibuprofen for PDA closure in premature infants.

Methods: One hundred and sixty infants (gestational age ≤ 34 weeks) with echocardiographically confirmed PDA were randomly assigned to receive either oral paracetamol (n = 80) or ibuprofen (n = 80). After the initial treatment course in both groups, the need for a second course was determined by echocardiographic evaluation. The main outcome was rate of ductal closure, and secondary outcomes were adverse effects and complications.

Result: The ductus was closed in 65 (81.2%) infants of the paracetamol group compared with 63 (78.8%) of the ibuprofen group. The 95% confidence interval of the difference between these groups was [-0.080,0.128], demonstrating that the effectiveness of paracetamol treatment was not inferior to that of ibuprofen. In fact, the incidence of hyperbilirubinemia or gastrointestinal bleeding in the paracetamol group was significantly lower than that of the ibuprofen group. No significant differences in other clinical side effects or complications were noted.

Conclusion: This comparison of drug efficacy and safety profiles in premature infants with PDA revealed that oral paracetamol was comparable to ibuprofen in terms of the rate of ductal closure and even showed a decreased risk of hyperbilirubinemia or gastrointestinal bleeding. Therefore, paracetamol may be accepted as a first-line drug treatment for PDA in preterm infants.

Trial registration: ChiCTR.org ChiCTR-TRC-12002177.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow diagram of study infants.
Figure 1. Flow diagram of study infants.

References

    1. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, et al. (2001) Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics (107): E1.
    1. Hamrick SEG, Hansmann G (2010) Patent Ductus Arteriosus of the Preterm Infant. Pediatrics (125): 10207.
    1. Capozzi G, Santoro G (2011) Patent ductus arteriosus: patho-physiology, hemodynamic effects and clinical complications. The Journal of Maternal-Fetal and Neonatal Medicine (24): 15–16.
    1. Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, et al. (2012) Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomized controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed (97) 279–283.
    1. Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, et al. (2011) Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr (158): 549–554.
    1. Aranda JV, FRCPC FAAP, Thomas R (2005) Intravenous Ibuprofen for Preterm Newborns. NeoReviews (6): e516–e523.
    1. Rao R, Bryowsky K, Mao J, Bunton D, McPherson C, et al. (2011) Gastrointestinal complications associated with ibuprofen therapy for patent ductus arteriosus. Journal of Perinatology (31): 465–470.
    1. Kushnir A, Pinheiro JMB (2011) Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts. BMC Clinical Pharmacology 11: 8.
    1. Shah NA, Hills NK, Waleh N, McCurnin D, Seidner S, et al. (2011) Relationship between Circulating Platelet Counts and Ductus Arteriosus Patency after Indomethacin Treatment. J Pediatr (158): 919–923.
    1. Ohlsson A, Walia R, Shah SS (2010) Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No: CD003481. DOI: .
    1. Adrouche-Amrani L, Green RS, Gluck KM, Lin J (2012) Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infant. BMC Pediatrics 12: 10.
    1. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, et al.. (2007) Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms J Pediatr (150) : 229–234, 234.e1.
    1. Malviya M, Ohlsson A, Shah S (2008) Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev (1): CD003951.
    1. Hammerman C, Bin-Nun A, Markowitz E, Schimmel MS, Kaplan M, et al. (2011) Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics (128): e1618–e1621.
    1. Maisels MJ, Watchko JF (2003) Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 88(6): F459–463.
    1. The International Classification of Retinopathy of Prematurity revisited (2005) Arch Ophthalmol. 123(7): 991–99.
    1. Bell MJ, Ternberg JL, Feigin RD, et al. (1978) Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 187: 1.
    1. Jobe AH, Bancalari E (2001) Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723.
    1. Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, et al.. (2013) An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofenresistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 98, F94.
    1. Yurttutan S, Yekta Oncel M, Arayici S, Uras N, Altug N, et al. (2013) A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med (26): 825–827.
    1. Yekta Oncel M, Yurttutan S, Degirmencioglu H, Uras N, Altug N, et al. (2013) Intravenous Paracetamol Treatment in the Management of Patent Ductus Arteriosus in Extremely Low Birth Weight Infants. Neonatology (103): 165–168.
    1. Heymann MA, Rudolph AM, Silverman NH (1976) Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med (295): 530–533.
    1. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE (1976) Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med (295): 526–529.
    1. Grèen K, Drvota V, Vesterqvist O (1989) Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins (37): 311–315.
    1. Lucas R, Warner TD, Vojnovic I, Mitchell JA (2005) Cellular mechanisms of acetaminophen: Role of cyclooxygenase. FASEB J (19): 635–637.
    1. Kulmacz RJ, Wang LH (1995) Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem (270): 24019–24023.
    1. Ahlfors CE (2004) Effect of ibuprofen on bilirubin-albumin binding. J Pediatr (144): 386–388.
    1. Cooper-Peel C, Brodersen R, Robertson A (1996) Does ibuprofen affect bilirubin-albumin binding in newborn infant serum. Pharmacol Toxicol (79): 297–299.
    1. Soligard HT, Nilsen OG, Bratlid D (2010) Displacement of bilirubin from albumin by ibuprofen in vitro. Pediatr Res (67): 614–618.
    1. Diot C, Kibleur Y, Desfrere L (2010) Effect of ibuprofen on bilirubin-albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus. Early Hum Dev (86): 315–317.
    1. Zecca E, Romagnoli C, De Carolis MP, Costa S, Marra R, et al. (2009) Does ibuprofen increase neonatal hyperbilirubinemia. Pediatrics (124): 480–484.
    1. Rheinlaender C, Helfenstein D, Walch E, Berns M, Obladen M, et al. (2009) Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr (98): 36–42.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren